There are currently 2029 clinical trials in Chicago, Illinois looking for participants to engage in research studies. Trials are conducted at various facilities, including Northwestern University, Rush University Medical Center, University of Chicago and University of Chicago Comprehensive Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013
Recruiting
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin). Approximately 1700 additional participants will be enrolled in an addendum to explore Lp(a) lowering with an alternative dosing schema.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Chicago Clinical Research Institute, Chicago, Illinois +1 locations
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Register for Updates
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
NCT06408259
Recruiting
The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
07/22/2025
Locations: Local Institution - 0093, Chicago, Illinois +1 locations
Conditions: Multiple Sclerosis, Relapsing-Remitting
Register for Updates
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
NCT06603571
Recruiting
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabetes. Participation in the study will last about 64 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/22/2025
Locations: Great Lakes Clinical Trials - Andersonville, Chicago, Illinois +1 locations
Conditions: Obesity, Overweight
Register for Updates
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
NCT06672549
Recruiting
The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/22/2025
Locations: Ann and Robert Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Obesity, Overweight
Register for Updates
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
NCT06672939
Recruiting
The main purpose of this study, performed under Master Protocol J4M-MC-PWMP, is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with obesity, or overweight with related comorbidities. Participation in the study will last about 18 months.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
07/22/2025
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Obesity, Overweight
Register for Updates
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05445778
Recruiting
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Rush University Medical Center /ID# 269583, Chicago, Illinois +1 locations
Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Register for Updates
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
NCT05548296
Recruiting
This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Northwestern Medicine, Chicago, Illinois +2 locations
Conditions: Endometrial Adenocarcinoma
Register for Updates
A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing
NCT05857930
Recruiting
This study will assess the efficacy and safety of daily OM-85 treatment compared to placebo in children aged 6 months to 5 years with recurrent wheezing
Gender:
ALL
Ages:
Between 6 months and 72 months
Trial Updated:
07/21/2025
Locations: Rush University Medical Center, Chicago, Illinois
Conditions: Recurrent Wheezing, Wheezing Lower Respiratory Illness
Register for Updates
Study of ALTO-300 in MDD
NCT05922878
Recruiting
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/21/2025
Locations: Site 310, Chicago, Illinois
Conditions: Major Depressive Disorder
Register for Updates
Race-Based Stress and Cognitive Training for MCI
NCT06330844
Recruiting
This a two phase project that aims to pilot a new adaptation (Phase 1) of Motivationally Enhanced Compensatory Cognitive Training for Mild Cognitive Impairment (ME-CCT; an originally VA-based cognitive rehabilitation manualized intervention for older adults with MCI, with a focus on the impact of stress on cognitive functioning; that integrates components from the Race Based Stress and Empowerment (RBSE) group for an increased focus on race-based stress and discrimination for racial minority old... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/21/2025
Locations: Rosalind Franklin University of Medicine and Science, Chicago, Illinois
Conditions: Mild Cognitive Impairment
Register for Updates
Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp
NCT06375811
Recruiting
A Phase 3 clinical trial of oral GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF, with a primary outcome of live birth rate. The investigators' central hypothesis is that in infertile woman with endometriosis undergoing in vitro fertilization-embryo transfer (IVF-ET), live birth rates will improve in those pretreated with GnRH antagonist compared to those not pretreated with GnRH antagonist.
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
07/21/2025
Locations: Northwestern University Department of Obstetrics and Gynecology, Chicago, Illinois
Conditions: Infertility, Endometriosis
Register for Updates
Study of ALTO-101 in Patients With Schizophrenia
NCT06502964
Recruiting
This is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers and measures of cognition. Additional goals are to assess pharmacokinetic (PK), safety, and tolerability of the recently developed ALTO-101T transdermal delivery system (TDS) formulation in a patient population.
Gender:
ALL
Ages:
Between 21 years and 55 years
Trial Updated:
07/21/2025
Locations: Site 5056, Chicago, Illinois
Conditions: Schizophrenia, Cognitive Impairment
Register for Updates